ArticleCurrent eye research2008
Toxicity and intraocular properties of a novel long-acting anti-proliferative and anti-angiogenic compound IMS2186.
Article in Current eye research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 16 citations in OpenAlex.
- Article
- Intravitreal inhibition of complement C5a reduces choroidal neovascularization in mice.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2015Article
- Synthesis and Biological Evaluation of Novel Homoisoflavonoids for Retinal Neovascularization.Journal of medicinal chemistry · 2015Article
- The effect of triamcinolone acetonide on laser-induced choroidal neovascularization in mice using a hypoxia visualization bio-imaging probe.Scientific reports · 2015Article
- Animal models of age-related macular degeneration and their translatability into the clinic.Expert review of ophthalmology · 2014Article
- [Pharmacological approach to treatment of proliferative vitreoretinopathy].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2013Review
- Pathogenic role of the Wnt signaling pathway activation in laser-induced choroidal neovascularization.Investigative ophthalmology & visual science · 2013Article
- Mechanisms of inflammation in proliferative vitreoretinopathy: from bench to bedside.Mediators of inflammation · 2012Review
- Improved assessment of laser-induced choroidal neovascularization.Microvascular research · 2010Article
- N-acetylcysteine suppresses retinal detachment in an experimental model of proliferative vitreoretinopathy.The American journal of pathology · 2010Article
- Targeting retinal and choroid neovascularization using the small molecule inhibitor carboxyamidotriazole.Brain research bulletin · 2010Article
- Effects of triamcinolone acetonide on vessels of the posterior segment of the eye.Molecular vision · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
Abstract
purposeTo investigate the intraocular properties and toxicity of IMS2186, a small molecule developed as an anti-choroidal neovascularization (anti-CNV) drug. MATERIALS AND
methodsCellular toxicity and mechanism of action was tested on cell lines in vitro. Intraocular studies used rabbits for drug dissolution as well as toxicity and rats for the treatment study as well as the toxicity confirmation study. Rabbits' eyes were injected with 2.5 mg of IMS2186 and observed for 36 weeks. Laser-induced CNV in rats was treated with IMS2186, Kenalog, or phosphate-buffered saline (pBS). Fluorescein angiography (FA) and immunohistochemical processing of the globes was performed.
resultsThe anti-proliferative IC(50) of IMS2186 for human fibroblast cells was 1.0-3.0 microM and 0.3-3.0 microM for human cancer cells; the IC(50) of IMS2186 to inhibit endothelial tube formation was 0.1-0.3 microM. The IC(50) of IMS2186 for inhibiting the production of pro-inflammatory cytokines was 0.3-1 microM. The IC(50) of IMS2186 for inhibiting macrophage migration was 1 micrM. These biological properties were not species specific. IMS2186 can be formulated as a suspension for long-lasting release and when delivered intraocularly, no intraocular toxicity was observed by slit lamp exam, fundus exam, intraocular pressure measurements, or by electroretinography. FA showed a reduction in the leakage in eyes treated with IMS2186 and triamcinolone acetonide; DAPI staining also showed significantly less cellularity in IMS2186-treated lesions as compared to PBS (p = 0.0025).
conclusionIMS2186 may be a safe intraocular therapeutic agent for intraocular proliferation and angiogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.